Dare Bioscience, Inc. Common Stock (DARE)

Price$1.88

Value ScoreD

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-5.75%

Price vs S&P 500 (4W)-31.63%

VGM Score55.10

Market Capitalization$28.16M

All Metrics

P/CF (Annual)4.70x

Book Value / Share (Quarterly)$0.05

P/TBV (Annual)3.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-53.12%

Cash Flow / Share (Quarterly)$-0.70

Price vs S&P 500 (YTD)-10.75%

Gross Margin (TTM)54.33%

Net Profit Margin (TTM)-679.26%

EPS (TTM)$-0.59

10-Day Avg Trading Volume0.25M

EPS Excl Extra (TTM)$-0.59

Revenue Growth (5Y)66.71%

EPS (Annual)$-1.20

ROI (Annual)-137.64%

Gross Margin (Annual)71.29%

Net Profit Margin (5Y Avg)-14661.44%

Cash / Share (Quarterly)$1.27

Revenue Growth QoQ (YoY)499.53%

ROA (Last FY)-41.26%

Revenue Growth TTM (YoY)1215.77%

EBITD / Share (TTM)$-0.47

ROE (5Y Avg)-867.89%

Operating Margin (TTM)-690.96%

Cash Flow / Share (Annual)$-0.71

P/B Ratio38.34x

P/B Ratio (Quarterly)36.08x

Net Income / Employee (Annual)$-638,100

EV / Revenue (TTM)13.41x

Net Interest Coverage (TTM)-92.72x

ROA (TTM)-26.37%

EPS Incl Extra (Annual)$-1.20

Current Ratio (Annual)1.14x

Quick Ratio (Quarterly)0.91x

3-Month Avg Trading Volume0.45M

52-Week Price Return-42.33%

EV / Free Cash Flow (Annual)1.98x

Revenue / Employee (TTM)$56,100

Tangible BV / Share (Quarterly)$-0.02

P/S Ratio (Annual)27.34x

Asset Turnover (Annual)0.03x

52-Week High$9.19

Operating Margin (5Y Avg)-12521.20%

EPS Excl Extra (Annual)$-1.20

CapEx CAGR (5Y)80.70%

Tangible BV CAGR (5Y)6.51%

26-Week Price Return2.17%

Quick Ratio (Annual)1.08x

13-Week Price Return19.75%

Total Debt / Equity (Annual)2.42x

Current Ratio (Quarterly)1.03x

Enterprise Value$15.81M

Revenue / Share Growth (5Y)10.80%

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)-38.32%

Revenue / Employee (Annual)$49,100

Pretax Margin (Annual)-1300.66%

Cash / Share (Annual)$1.70

3-Month Return Std Dev156.51%

Net Income / Employee (TTM)$-381,200

ROE (Last FY)-471.37%

Net Interest Coverage (Annual)-229.44x

EPS Basic Excl Extra (Annual)$-1.20

P/FCF (TTM)22.75x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)8.40x

EPS Incl Extra (TTM)$-0.59

Receivables Turnover (Annual)0.00x

ROI (TTM)-89.74%

P/S Ratio (TTM)23.90x

Pretax Margin (5Y Avg)-14661.44%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$0.13

Price vs S&P 500 (52W)-66.70%

Year-to-Date Return-2.59%

5-Day Price Return-14.16%

EPS Normalized (Annual)$-1.20

ROA (5Y Avg)-68.25%

Net Profit Margin (Annual)-1300.66%

Month-to-Date Return-15.70%

Cash Flow / Share (TTM)$-0.48

EBITD / Share (Annual)$-1.07

Operating Margin (Annual)-1315.52%

LT Debt / Equity (Annual)1.90x

ROI (5Y Avg)-801.15%

LT Debt / Equity (Quarterly)7.57x

EPS Basic Excl Extra (TTM)$-0.59

P/B Ratio (Annual)9.70x

Pretax Margin (TTM)-679.26%

Book Value / Share (Annual)$0.20

Price vs S&P 500 (13W)11.49%

Beta1.09x

P/FCF (Annual)5.84x

Revenue / Share (TTM)$0.08

ROE (TTM)-373.17%

52-Week Low$1.27

vGradeD

gGradeA

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.20est. -0.30

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.10

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
DAREDare Bioscience, Inc. Common Stock	D	A	C	$1.88
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Dare Bioscience is a biopharmaceutical company developing therapies in women's health, focused on contraception, fertility, and sexual health. The company's first approved product, XACIATO, is a prescription vaginal gel for treating bacterial vaginosis in females ages 12 and older. Its pipeline includes two clinical-stage candidates: Ovaprene and Sildenafil Cream.